GlassScriptPhysician profile
Wajihuddin Syed
NPI 1417389099
$3,625.49
in general payments reported to CMS, 2019-2025
39 companies · $2,147 in 2025
The $2,147 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.61 · 2020: $304 · 2021: $28.62 · 2022: $33.88 · 2023: $144 · 2024: $903 · 2025: $2,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $295.15 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $221.62 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $204.20 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $150.21 | 2019-2025 | Tecentriq, Itovebi, Phesgo |
| Gilead Sciences, INC. | $144.12 | 2021-2025 | Trodelvy |
| Amgen INC. | $124.67 | 2020 | |
| Pfizer INC. | $109.64 | 2019-2025 | |
| Genzyme Corporation | $98.27 | 2024-2025 | |
| Janssen Biotech, INC. | $97.57 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $96.63 | 2024-2025 | Lynparza, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $83.96 | 2020-2025 | Opdualag, Opdivo |
| Abbvie INC. | $75.49 | 2024-2025 | |
| Array Biopharma INC | $72.79 | 2024-2025 | Lorbrena, Mektovi, Braftovi |
| Glaxosmithkline, LLC. | $65.03 | 2023-2025 | Jemperli, Zejula |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wajihuddin Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.